IL152289A0 - Method and composition for inhibiting h.pylori infection in a mammalian tissue - Google Patents

Method and composition for inhibiting h.pylori infection in a mammalian tissue

Info

Publication number
IL152289A0
IL152289A0 IL15228902A IL15228902A IL152289A0 IL 152289 A0 IL152289 A0 IL 152289A0 IL 15228902 A IL15228902 A IL 15228902A IL 15228902 A IL15228902 A IL 15228902A IL 152289 A0 IL152289 A0 IL 152289A0
Authority
IL
Israel
Prior art keywords
inhibiting
composition
mammalian tissue
pylori infection
pylori
Prior art date
Application number
IL15228902A
Other languages
English (en)
Original Assignee
Vectabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectabiotics Ltd filed Critical Vectabiotics Ltd
Priority to IL15228902A priority Critical patent/IL152289A0/xx
Publication of IL152289A0 publication Critical patent/IL152289A0/xx
Priority to PCT/IB2003/004453 priority patent/WO2004034957A2/en
Priority to JP2004544577A priority patent/JP2006506367A/ja
Priority to EP03758376A priority patent/EP1567181A4/de
Priority to CA002503325A priority patent/CA2503325A1/en
Priority to AU2003274392A priority patent/AU2003274392A1/en
Priority to US10/682,937 priority patent/US7271146B2/en
Priority to US11/351,001 priority patent/US20060135406A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL15228902A 2002-10-14 2002-10-14 Method and composition for inhibiting h.pylori infection in a mammalian tissue IL152289A0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IL15228902A IL152289A0 (en) 2002-10-14 2002-10-14 Method and composition for inhibiting h.pylori infection in a mammalian tissue
PCT/IB2003/004453 WO2004034957A2 (en) 2002-10-14 2003-10-09 Methods for treatment of helicobacter pylori-associated disorders
JP2004544577A JP2006506367A (ja) 2002-10-14 2003-10-09 ヘリコバクター・ピロリ関連疾患の治療方法
EP03758376A EP1567181A4 (de) 2002-10-14 2003-10-09 Verfahren zur behandlung von helicobacter pylori-assoziierten erkrankungen
CA002503325A CA2503325A1 (en) 2002-10-14 2003-10-09 Methods for treatment of helicobacter pylori-associated disorders
AU2003274392A AU2003274392A1 (en) 2002-10-14 2003-10-09 Methods for treatment of helicobacter pylori-associated disorders
US10/682,937 US7271146B2 (en) 2002-10-14 2003-10-14 Methods for treatment of Helicobacter pylori-associated disorders
US11/351,001 US20060135406A1 (en) 2002-10-14 2006-02-09 Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL15228902A IL152289A0 (en) 2002-10-14 2002-10-14 Method and composition for inhibiting h.pylori infection in a mammalian tissue

Publications (1)

Publication Number Publication Date
IL152289A0 true IL152289A0 (en) 2003-05-29

Family

ID=29765063

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15228902A IL152289A0 (en) 2002-10-14 2002-10-14 Method and composition for inhibiting h.pylori infection in a mammalian tissue

Country Status (7)

Country Link
US (1) US7271146B2 (de)
EP (1) EP1567181A4 (de)
JP (1) JP2006506367A (de)
AU (1) AU2003274392A1 (de)
CA (1) CA2503325A1 (de)
IL (1) IL152289A0 (de)
WO (1) WO2004034957A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2536906A1 (en) * 2003-08-27 2005-03-10 Vecta Ltd. Compositions for treating pathologies that necessitate suppression of gastric acid secretion
WO2005027955A1 (en) * 2003-09-24 2005-03-31 Vecta Ltd. Oral compositions for the stimulation of gastric acid secretion comprising pentagastrin
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
AU2007278986B2 (en) * 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
CA2699100A1 (en) * 2007-09-11 2009-04-02 Dorian Bevec Use of a peptide as a therapeutic agent
WO2009091986A1 (en) * 2008-01-16 2009-07-23 Lankenau Institute For Medical Research Use of proton pump inhibitors as drug delivery adjuvants
EP2601947A1 (de) * 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Kombinationspräparat mit fester Dosierung zur Behandlung von Erkrankungen einhergehend mit Helicobacter pylori
US9700514B1 (en) * 2014-08-20 2017-07-11 Darren Rubin Single solid oral dosage forms for treating Helicobacter pylori infection and duodenal ulcer disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891356A (en) * 1987-07-15 1990-01-02 Brigham & Women's Hospital Proteinase inhibitors for treatment of gastrointestinal ulcer disease
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
DE69916273T2 (de) * 1998-06-18 2005-05-19 Vecta Ltd. Verwendung von gastrin fragmenten oder sythetischen analogen von gastrin zur herstellung eines arzneimittels zur behandlung der helicobacter pylori assozierten störungen
US7365047B1 (en) * 1999-09-28 2008-04-29 The Regents Of The University Of California Use of pentagastrin to inhibit gastric acid secretion or as a diuretic
FR2832311B1 (fr) * 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations

Also Published As

Publication number Publication date
AU2003274392A1 (en) 2004-05-04
EP1567181A4 (de) 2006-04-12
WO2004034957A3 (en) 2005-07-07
JP2006506367A (ja) 2006-02-23
US20040082514A1 (en) 2004-04-29
EP1567181A2 (de) 2005-08-31
CA2503325A1 (en) 2004-04-29
WO2004034957A2 (en) 2004-04-29
US7271146B2 (en) 2007-09-18

Similar Documents

Publication Publication Date Title
EP1157707B8 (de) Mittel und Verfahren zum Verformen von Weichgewebe
GB0110288D0 (en) Composition and treatment method
AU6832101A (en) Composition and method
AU2002236626A1 (en) Compositions and methods for treating hyperpigmentation
AU2003232044A8 (en) Composition and method for dermatological treatment
AP2147A (en) A composition for treating aids and associated conditions.
GB0219642D0 (en) Method and device for preparing tissues sections
IL152289A0 (en) Method and composition for inhibiting h.pylori infection in a mammalian tissue
AU2003256526A1 (en) Arrangements and methods for treating a subject
AU2003240410A8 (en) Piezoceramic composition, piezoceramic body comprising said composition and a method for producing said composition and said body
AU2003296885A8 (en) Composition and method for imaging cells
AU2002245510A1 (en) Method and composition for embalming
AU2003262840A1 (en) Composition and method for treating skin
AU2003295574A8 (en) Method and compositions for temporarily incapaciting subjets
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
AU2003303948A8 (en) Compositions and methods for preventing infection
AU2003275069A8 (en) Compositions and methods for preventing infection
AU2003233038A1 (en) Method and device for obtaining plant ingredients
EP1272512A4 (de) Immunokin-zusammensetzung und verfahren
GB0229445D0 (en) Process,composition and use
GB0203528D0 (en) Process and composition
GB0107033D0 (en) Method and composition
GB0211889D0 (en) Composition and method
GB0210497D0 (en) Composition and method
GB0211220D0 (en) Composition and method